Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Thursday
Apr 28th
Repaglinide Print E-mail
There is on-going development of  generic  EU CTD Dossier of Repaglinide, tablets, 0.5/1/2 mg.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.

More details at: http://www.rxlist.com/prandin-drug.htm.

Comments
Search RSS
Tanvir Halim  - rapaglinide   |2012-09-01 09:19:57
Is your formulation identical to a reference product and does it
pass
comparative dissolution ?
Only registered users can write comments!

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

Read also at Pharmaceutical Licensing Network
Related News
Newer news items
Related Items
Farmavita.Net - The Pharmaceutical Licensing Network
 
< Prev   Next >
Advertisement
 

Featured Partners

 
marketing_products150x150.jpg  
supplier_management.jpg  
150x150_admet.jpg
150x150_pfs_west_coast.jpg 
 pain150x150.jpg
150x150_copy.jpg
ppfe1_150x150_copy.jpg 
150_x_150_biobanking_20-21_june.jpg 
150x150_latamma16.gif  
sop150x150.jpg  

Follow us on:




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 285 guests online

Farmavita.Net RSS News


Reports

rbdl0002_innovations-in-inj.gif 

Events

vaccines-2016_150x150.jpg

Reports

rbhc0264_privatehealthcare.gif 

REPORTS

farmavita_research-store.gif